良性前立腺肥大症:治療薬開発パイプライン分析

【英語タイトル】Benign Prostatic Hyperplasia - Pipeline Review, H2 2017

Global Markets Directが出版した調査資料(GMDHC9904IDB)・商品コード:GMDHC9904IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2017年11月14日
・ページ数:113
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における良性前立腺肥大症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・良性前立腺肥大症の概要
・良性前立腺肥大症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・良性前立腺肥大症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・良性前立腺肥大症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・良性前立腺肥大症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Benign Prostatic Hyperplasia – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia – Pipeline Review, H2 2017, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 5, 5, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Benign Prostatic Hyperplasia – Overview 9
Benign Prostatic Hyperplasia – Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 17
Benign Prostatic Hyperplasia – Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Benign Prostatic Hyperplasia – Companies Involved in Therapeutics Development 26
Addex Therapeutics Ltd 26
AndroScience Corp 26
Aphios Corp 26
Astellas Pharma Inc 27
BCWorld Pharm Co Ltd 27
Biolab Farmaceutica Ltda 28
Chong Kun Dang Pharmaceutical Corp 28
Curadis GmbH 29
Dongkook Pharmaceutical Co Ltd 29
GL Pharm Tech Corp 30
Health Ever Bio-Tech Co Ltd 30
Jeil Pharmaceutical Co Ltd 30
MEI Pharma Inc 31
Meiji Seika Pharma Co Ltd 31
Mezzion Pharma Co Ltd 32
Nymox Pharmaceutical Corp 32
Ono Pharmaceutical Co Ltd 32
OPKO Health Inc 33
SK Chemicals Co Ltd 33
Sophiris Bio Inc 34
Sun Pharma Advanced Research Company Ltd 34
The Female Health Company 35
XuanZhu Pharma Co Ltd 35
Yungjin Pharm Co Ltd 36
Yuyu Pharma Inc 36
Benign Prostatic Hyperplasia – Drug Profiles 38
(alfuzosin hydrochloride ER + tadalafil) – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
(dutasteride + tadalafil) – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
(solifenacin + tamsulosin) – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
(tadalafil + tamsulosin hydrochloride) – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ADX-68692 – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ASC-JM.X2 – Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
AUS-131 – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
BCWPE-004 – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
BL-214 – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
CR-1447 – Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
fexapotide triflutate – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
KKM-1202 – Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
L-1AD3 – Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
MCS-2 – Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
NCE-403 – Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
ONO-8430506 – Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
S-0131632 – Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
sirolimus – Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia – Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Sperol – Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology – Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
talaporfin sodium – Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
tamsulosin hydrochloride – Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
tamsulosin hydrochloride CR – Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
tamsulosin hydrochloride DR – Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
tamsulosin SR – Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
tertomotide – Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
topsalysin – Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
TT-701 – Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
udenafil – Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
XZP-5849 – Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
YBH-1603 – Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
YOB-1604 – Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
YY-201 – Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Benign Prostatic Hyperplasia – Dormant Projects 98
Benign Prostatic Hyperplasia – Discontinued Products 101
Benign Prostatic Hyperplasia – Product Development Milestones 102
Featured News & Press Releases 102
Nov 07, 2017: Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana 102
Oct 13, 2017: Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah 103
Oct 10, 2017: Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12 103
Sep 25, 2017: Nymox Announces October 12 Symposium for Company’s BPH Drug at American Urological Association Meeting 104
Sep 15, 2017: Mayne Pharma Adds Urorec (silodosin) Capsules to Its Australian Portfolio 104
Sep 14, 2017: Nymox Announces New Symposium for Companys BPH Drug at American Urological Association Meeting October 5 105
Sep 14, 2017: Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia 105
Aug 07, 2017: Nymox Announces Symposium for Company’s BPH Drug at American Urological Association Meeting in September 106
May 31, 2017: Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials 106
May 08, 2017: NYMOX Files For Approval of First In Class Prostate Drug in Europe 108
May 03, 2017: NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe 108
Mar 29, 2017: Nymox Provides Update on Fexapotide Development 109
Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug – Fadanafil 109
Nov 29, 2016: Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy 109
Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692 111
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 112
Disclaimer 113

List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017 10
Number of Products under Development by Companies, H2 2017 12
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Number of Products under Development by Universities/Institutes, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Universities/Institutes, H2 2017 17
Number of Products by Stage and Target, H2 2017 19
Number of Products by Stage and Mechanism of Action, H2 2017 21
Number of Products by Stage and Route of Administration, H2 2017 23
Number of Products by Stage and Molecule Type, H2 2017 25
Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2017 26
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H2 2017 26
Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H2 2017 27
Benign Prostatic Hyperplasia - Pipeline by Astellas Pharma Inc, H2 2017 27
Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H2 2017 28
Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2017 28
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 29
Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2017 29
Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017 29
Benign Prostatic Hyperplasia - Pipeline by GL Pharm Tech Corp, H2 2017 30
Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017 30
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017 31
Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H2 2017 31
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017 31
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H2 2017 32
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H2 2017 32
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 33
Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H2 2017 33
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H2 2017 34
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H2 2017 34
Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 35
Benign Prostatic Hyperplasia - Pipeline by The Female Health Company, H2 2017 35
Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2017 36
Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Co Ltd, H2 2017 36
Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H2 2017 37
Benign Prostatic Hyperplasia - Dormant Projects, H2 2017 98
Benign Prostatic Hyperplasia - Dormant Projects, H2 2017 (Contd..1), H2 2017 99
Benign Prostatic Hyperplasia - Dormant Projects, H2 2017 (Contd..2), H2 2017 100
Benign Prostatic Hyperplasia - Discontinued Products, H2 2017 101

List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Number of Products under Development by Universities/Institutes, H2 2017 14
Number of Products by Top 10 Targets, H2 2017 18
Number of Products by Stage and Top 10 Targets, H2 2017 18
Number of Products by Top 10 Mechanism of Actions, H2 2017 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 20
Number of Products by Top 10 Routes of Administration, H2 2017 22
Number of Products by Stage and Top 10 Routes of Administration, H2 2017 22
Number of Products by Molecule Types, H2 2017 24
Number of Products by Stage and Molecule Types, H2 2017 24

【レポートのキーワード】

良性前立腺肥大症

★調査レポート[良性前立腺肥大症:治療薬開発パイプライン分析] (コード:GMDHC9904IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[良性前立腺肥大症:治療薬開発パイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆